Towards Multiomics-Based Dissection of Anti-EGFR Sensitivity in Colorectal Cancer.
Where this comes from
- Record sourced from PubMed, PMID 37594733.
- Also identified by DOI 10.1158/1078-0432.CCR-23-1954 and PMC identifier 10570674.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Overexpression of the EGFR ligands amphiregulin (AREG)/epiregulin (EREG) may be a surrogate of EGFR dependency regardless of sidedness in metastatic colorectal cancer. High AREG/EREG may be coupled with negative hyper-selection (i.e., lack of genomic drivers of primary resistance beyond RAS and BRAF) to identify patients with right-sided tumors and potential sensitivity to EGFR blockade. See related article by Williams et al., p. 4153.
Medical subject headings
- Colorectal Neoplasms
- Colonic Neoplasms
- Rectal Neoplasms